



JC10 Rec'd PCT/PTO 02 NOV 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

~~In re~~ Applicant:

Daphne ATLAS et al

Serial No.: 10/522,766

Filed: February 01, 2005

For: TREATMENT OF MULTIPLE SCLEROSIS WITH
BRAIN TARGETED ANTI-OXIDANT
COMPOUNDS

Examiner: N/A

Group Art Unit: Not yet Available

Attorney
Docket: 29287

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Respectfully submitted,
Mairi O' Meara

Martin Moynihan
Registration No. 40,338

Dated: October 31, 2005



10 Rec'd PCT/PTO 02 NOV 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U. S. DEPARTMENT

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complexity of Known

Complete if Known	
Application Number	10/522,766
Filing Date	February 01, 2005
First Named Inventor	Daphne ATLAS et al
Art Unit	Not yet Available
Examiner Name	Not yet Available

Sheet 1 of 3 Attorney Docket Number

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
	8	PCT WO 98/29375	09-9-1998	Atlas et al.	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.



10 Rec'd PCT/PTC 02 NOV 2005

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE: U.S. GOVERNMENT - FORM 1040
Information unless it contains a valid OMB control number.

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/522,766
Filing Date	February 01, 2005
First Named Inventor	Daphne ATLAS et al
Group Art Unit	Not yet Available
Examiner Name	Not yet Available

(use as many sheets as necessary)				
Sheet	2	Of	3	Attorney Docket Number
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	9	Aschner "Astrocyte Metallothioneins (MTs) and Their Neuroprotective Role", Annals New York Academy of Sciences, 825: 334-347, 1997.		
	10	Aschner et al. "Metallothioneins in Brain - The Role in Physiology and Pathology", Toxicology and Applied Pharmacology, 142: 229-242, 1997.		
	11	Bartnik et al. "Macrophages: Their Myelinotrophic or Neurotoxic Actions Depend Upon Tissue Oxidative Stress", Multiple Sclerosis, 6: 37-42, 2000.		
	12	??? "L- and D-Penicillamine Hydrochlorides", Biochemical Preparations, 3: 111-118, 1953.		
	13	Brown et al. "Role of Microglia and Host Prion Protein in Neurotoxicity of A Prion Protein Fragment", Nature, 380: 345-347, 1996.		
	14	Butterfield et al. "Lipid Peroxidation and Protein Oxidation in Alzheimer's Disease Brain: Potential Causes and Consequences Involving Amyloid β -Peptide-Associated Free Radical Oxidative Stress", Free Radical Biology & Medicine, 32(11): 1050-1060, 2002.		
	15	Cross et al. "Inducible Nitric Oxide Synthase Gene Expression and Enzyme Activity Correlate With Disease Activity in Murine Experimental Autoimmune Encephalomyelitis", Journal of Neuroimmunology, 71: 145-153, 1996.		
	16	Cross et al. "Aminoguanidine, An Inhibitor of Inducible Nitric Oxide Synthase, Ameliorates Experimental Autoimmune Encephalomyelitis in SJL Mice", The Journal of Clinical Investigation, 93: 2684-2690, 1994.		
	17	Ebadi et al. "Expression and Regulation of Brain Metallothionein", Neurochemistry International, 27(1): 1-22, 1995.		
	18	Espejo et al. "Differential Expression of Metallothioneins in the CNS of Mice With Experimental Autoimmune Encephalomyelitis", Neuroscience, 105(4): 1055-1065, 2001.		
	19	Fahn et al. "The Oxidant Stress Hypothesis in Parkinson's Disease: Evidence Supporting It", Annals in Neurology, 32: 804-812, 1992.		
	20	Fenyk-Melody et al. "Experimental Autoimmune Encephalomyelitis Is Exacerbated in Mice Lacking the NOS2 Gene", The Journal of Immunology, 160: 2940-2946, 1998.		
	21	Fingl et al. "General Principles", The Pharmacological Basis of Therapeutics, Chap.1: 1-46, 1975.		
	22	Hooper et al. "Local Nitric Oxide Production in Viral and Autoimmune Diseases of the Central Nervous System", Proc. Natl. Acad. Sci. USA, 92: 5312-5316, 1995.		
	23	Lassmann et al. "Immunopathology of Multiple Sclerosis: Report on An International Meeting Held at the Institute of Neurology of the University of Vienna", Journal of Neuroimmunology, 86: 213-217, 1998.		
	24	Lazo et al. "Enhanced Sensitivity to Oxidative Stress in Cultured Embryonic Cells From Transgenic Mice Deficient in Metallothionein I and II Genes", The Journal of Biological Chemistry, 270(10): 5506-5510, 1995.		
	25	Lin et al. "Nitric Oxide Localized to Spinal Cords of Mice With Experimental Allergic Encephalomyelitis: An Electron Paramagnetic Resonance Study", Journal of Experimental Medicine, 178: 643-648, 1993.		
	26	Martin et al. "Immunological Aspects of Demyelinating Diseases", Annual Reviews of Immunology, 10: 153-187, 1992.		
	27	Okuda et al. "Nitric Oxide Via An Inducible Isoform of Nitric Oxide Synthase Is A Possible Factor to Eliminate Inflammatory Cells From the Central Nervous System of		

NOV 02 2005	28	Mice With Experimental Allergic Encephalomyelitis", Journal of Neuroimmunology, 73: 107-116, 1997.
NOV 02 2005	29	Olanow "Oxidative Reactions in Parkinson's Disease", Neurology, 44(3 suppl.3): 32-37, 1990.
NOV 02 2005	30	Ruuls et al. "Aggravation of Experimental Allergic Encephalomyelitis (EAE) by Administration of Nitric Oxide (NO) Synthase Inhibitors", Clinical and Experimental Immunology, 103: 467-474, 1996.
NOV 02 2005	31	Sahrbacher et al. "Mice With An Inactivation of the Inducible Nitric Oxide Synthase Gene Are Susceptible to Experimental Autoimmune Encephalomyelitis", European Journal of Immunology, 28: 1332-1338, 1998.
NOV 02 2005	32	Schwarz et al. "Metallothionein Protects Against the Cytotoxic and DNA-Damaging Effects of Nitric Oxide", Proc. Natl. Acad. Sci. USA, 92: 4452-4456, 1995.
NOV 02 2005	33	Shiraga et al. "The Effects of 6-Hydroxydopamine and Oxidative Stress on the Level of Brain Metallothionein", Neurochemistry International, 23(6): 561-566, 1993.
	34	Steinman et al. "Multiple Sclerosis: Deeper Understanding of Its Pathogenesis Reveals New Targets for Therapy", Annual Reviews of Neuroscience, 25:491-505, 2002.
	35	Syburra et al. "Oxidative Stress in Patients With Multiple Sclerosis", Ukrainian Biochemical Journal, 71(3): 112-115, 1999.
	36	Thomas et al. "β-Amyloid-Mediated Vasoactivity and Vascular Endothelial Damage", Nature, 380: 168-171, 1996.
	37	Thornalley et al. "Possible Role for Metallothionein in Protection Against Radiation-Induced Oxidative Stress. Kinetics and Mechanism of Its Reaction With Superoxide and Hydroxyl Radicals", Biochimica et Biophysica Acta, 827: 36-44, 1985.
	38	Tsangaris et al. "Metallothionein Expression Prevents Apoptosis: A Study With Antisense Phosphorothioate Oligodeoxynucleotides in A Human T Cell Line", Anticancer Research, 18: 2423-2434, 1998.
	39	Vladimirova et al. "Oxidative Damage to DNA in Plaques of MS Brains", Multiple Sclerosis, 4: 413-418, 1998.

Signature		Considered
-----------	--	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.